Latest Articles
-
Should You Buy Pfizer Stock Ahead of Its Q2 Results?
Pfizer (NYSE: PFE) is scheduled to report its Q2 2022 results on Thursday, July 28, and we expect it to post revenue and earnings well above the consensus estimates. Its Covid-19 vaccine and the antiviral pill will continue to drive revenue growt...
-
Should You Buy, Sell, Or Hold Pfizer Stock At $52?
After an 8% fall year-to-date, at the current levels, we believe Pfizer stock (NYSE: PFE) has some room for growth. PFE stock fell from $57 in early January to $52 now. The YTD -8% return for PFE marks an outperformance with -19% returns for th...
-
Here’s A Better Pick Over FedEx Stock
We think that Pfizer stock (NYSE: PFE) currently is a better pick compared to FedEx stock (NYSE: FDX), despite it being the more expensive of the two, trading at 3.3x trailing revenues compared to 0.6x for FedEx. The gap in the valuation of ...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) plans to acquire Biohaven Pharmaceutical, a company that specializes in migraine treatments, in a deal valued at about $11.6 billion. Why? Pfizer is flush with cash from its Covid-19 vaccine and is looking at acquisiti...
-
What To Expect From Pfizer’s Q1?
Pfizer (NYSE: PFE) is scheduled to report its Q1 2022 results on Tuesday, May 3. We expect the company to likely post revenue and earnings below the consensus estimates. The revenue from its Covid-19 vaccine and antiviral pill sales may be lower ...
-
Company Of The Day: Pfizer
What? A recently published study from Israel on booster shots of Pfizer (NYSE:PFE) and its partner BioNTech’s Covid-19 vaccine indicates that a fourth dose of the vaccine (second booster) lowered the risk of severe disease in the elderly, ...
-
Will Pfizer Stock See Higher Levels After A 10% Rise In A Month?
The stock price of Pfizer (NYSE: PFE) has seen a rise of 10% over the last month, while it is down 6% YTD. The increase over the previous month can partly be attributed to Pfizer’s acquisition of Arena Pharmaceuticals for $6.7 billion. Th...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) said that the U.S. FDA granted the company’s vaccine candidate targeted at respiratory syncytial virus PF-06928316 (RSVpreF) a Breakthrough Therapy designation. Why? The Breakthrough Therapy designation is meant ...
-
Are Covid-19 Treatment Stocks A Buy As Global Infections Rise Again?
Our indicative theme on Covid-19 Treatment Stocks – which includes biotech and pharma companies selling or developing treatments for the Covid-19 virus – has declined by about 2% year-to-date, outperforming the S&P 500 which has declined by...
-
What’s Next For Pfizer Stock After A 10% Fall In A Month?
The stock price of Pfizer (NYSE: PFE) has seen a fall of 10% over the last month, while it is up 4% in a week. The decline over the previous month can be attributed to Pfizer’s underwhelming guidance for its Covid-19 vaccine and treatment...
-
Does The Current Dip In Pfizer Stock Offer A Buying Opportunity?
[Updated: Feb 10, 2022] Pfizer Q4 Earnings Update The stock price of Pfizer (NYSE: PFE) has seen a fall of 8% over the last month, while it is down over 3% in a week. The recent decline can be attributed to the company’s mixed Q4 results...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) posted better than expected Q4 2021 earnings, with adjusted EPS coming in at $1.08, up from about $0.43 in Q4 2020. However, revenue growth, which came in at 104% year-over-year, missed estimates. Why? Growth was drive...
-
Forecast Of The Day: Pfizer’s Oncology Revenue
What? Pfizer’s (NYSE:PFE) Oncology Revenue, which includes revenues from Sutent, Xalkori, Inlyta, Ibrance, and other productions, rose from around $9 billion in 2019 to about $11 billion in 2020. We expect the metric to rise to around $12...
-
Will Pfizer Stock See Higher Levels After A Large 18% Rise In A Month?
[Updated: Dec 16, 2021] Pfizer Stock Rise The stock price of Pfizer (NYSE: PFE) has outperformed the broader indices. While the S&P500 index has seen a rise of 1% over the last month or so, PFE stock is up a solid 19%. This also compares wit...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) said that the third dose of its Covid-19 shot was able to neutralize the omicron variant of the novel coronavirus in lab studies. However, a two-dose regimen was much less effective at stopping the concerning new virus v...
